Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
MEI Pharma begins ME-344 Phase Ib clinical study in patients with solid tumors

MEI Pharma begins ME-344 Phase Ib clinical study in patients with solid tumors

Research roundup: Structural concerns in ACOs; public's view of mandated contraception coverage

Research roundup: Structural concerns in ACOs; public's view of mandated contraception coverage

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

Targeted Medical Pharma signs agreement with Lebanon based company, ATL

UC pain researcher solves a long-standing scientific mystery

UC pain researcher solves a long-standing scientific mystery

Researcher wins 2014 Abraham White Distinguished Science Award for contributions in treatment of neurological diseases

Researcher wins 2014 Abraham White Distinguished Science Award for contributions in treatment of neurological diseases

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

Longer looks: The politics of face and hand transplants; Apple's Healthbook; connecting income to life expectancy

Longer looks: The politics of face and hand transplants; Apple's Healthbook; connecting income to life expectancy

Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

Study provides insight into the mechanisms underlying diabetic peripheral neuropathy

NC-stat DPNCheck is a fast, accurate point-of-care test for diabetic peripheral neuropathy

NC-stat DPNCheck is a fast, accurate point-of-care test for diabetic peripheral neuropathy

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Researchers evaluate mangafodipir for relief of oxaliplatin-associated neuropathies

Researchers evaluate mangafodipir for relief of oxaliplatin-associated neuropathies

Scientists continue work to end chemotherapy pain

Scientists continue work to end chemotherapy pain

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

UT Dallas professor awarded $2.3 million NIH grant to continue prosthetics, orthotics research

UT Dallas professor awarded $2.3 million NIH grant to continue prosthetics, orthotics research

Vasculitis damage swift, accumulating

Vasculitis damage swift, accumulating

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases